ml2  (Magic Leap Inc)

Journal: Cardiovascular and Interventional Radiology

Article Title: Optical See-Through and Video See-Through Head-Mounted Displays for Percutaneous Biopsies: A Comparative Phantom Study

doi: 10.1007/s00270-026-04360-3

Figure Lengend Snippet: 2D registration task for the ML2 and AVP. A Model created with blender and rendered on the ML2 and AVP. B Example of the task with the ML2. Each color line represents a different viewing direction. The distance between the lines was measured and plotted in C. C Distance of the different tests with the HMDs, n = 5 participants. Results shown as mean and standard deviation, two-way ANOVA. ML2, Magic Leap 2, AVP, Apple Vision Pro

Article Snippet: We evaluated the ML2 (Magic Leap, Inc., Plantation, FL, USA) as an OST device and the AVP (Apple Inc., Cupertino, CA, USA) as a VST device (Supplementary Fig. 1).

Techniques: Standard Deviation

Journal: Cardiovascular and Interventional Radiology

Article Title: Optical See-Through and Video See-Through Head-Mounted Displays for Percutaneous Biopsies: A Comparative Phantom Study

doi: 10.1007/s00270-026-04360-3

Figure Lengend Snippet: Hologram of the phantom was overlaid on the physical phantom using the HMDs. A View of the phantom. B 3D model used for the ML2 and the AVP. Target lesions used on the study, yellow circle represents Lesion 1 and blue circle represents Lesion 2. C Puncture procedure using the AVP. D View from the AVP during puncture. ML2, Magic Leap 2, AVP, Apple Vision Pro

Article Snippet: We evaluated the ML2 (Magic Leap, Inc., Plantation, FL, USA) as an OST device and the AVP (Apple Inc., Cupertino, CA, USA) as a VST device (Supplementary Fig. 1).

Techniques:

Journal: Cardiovascular and Interventional Radiology

Article Title: Optical See-Through and Video See-Through Head-Mounted Displays for Percutaneous Biopsies: A Comparative Phantom Study

doi: 10.1007/s00270-026-04360-3

Figure Lengend Snippet: Distance of the tip of needle to the center of target lesion for the punctures with and without the HMDs. A Lesion 1. B Lesion 2. Angle offset of the needle to the center of target lesion for the punctures with and without the HMDs. C Lesion 1. D Lesion 2. Data represented as mean and standard deviation and analyzed with a two-way ANOVA. ML2, Magic Leap 2, AVP, Apple Vision Pro

Article Snippet: We evaluated the ML2 (Magic Leap, Inc., Plantation, FL, USA) as an OST device and the AVP (Apple Inc., Cupertino, CA, USA) as a VST device (Supplementary Fig. 1).

Techniques: Standard Deviation

Journal: Cardiovascular and Interventional Radiology

Article Title: Optical See-Through and Video See-Through Head-Mounted Displays for Percutaneous Biopsies: A Comparative Phantom Study

doi: 10.1007/s00270-026-04360-3

Figure Lengend Snippet: Mental and physical load evaluation of the ML2 and AVP. A NASA-TLX scores given by the beginner radiologist after the punctures. B NASA-TLX scores given by the advanced radiologist after the punctures. Data plotted as a Box and Whiskers graph, with 5–95 percentile. Statistical evaluation with a two-way ANOVA with Tukey’s multiple comparison test. ML2, Magic Leap 2, AVP, Apple Vision Pro

Article Snippet: We evaluated the ML2 (Magic Leap, Inc., Plantation, FL, USA) as an OST device and the AVP (Apple Inc., Cupertino, CA, USA) as a VST device (Supplementary Fig. 1).

Techniques: Comparison

Journal: bioRxiv

Article Title: Single-domain antibodies targeting the pan-T-cell markers CD2 and CD7 as universal immunotherapy T-cell tracers

doi: 10.64898/2025.12.23.693936

Figure Lengend Snippet: A , ELISA-based analysis of IFNγ, IL-2, GM-CSF and TNFα-secretion of TCR-transduced CD8 + T cells after 24 h incubation with either CD2-sdAb (orange), CD27-sdA (blue) and R3b23-sdAb as a control (grey) in three different tumor cell lines that have been transduced with HLA-B*07:02 (ML2-B7, NB4-B7, HL60-B7). Results of triplicates are depicted with mean +/- standard deviation (sd). B , Proliferation of target tumor cells (624.38 Mel) was monitored by impedance measurement every 30 min for 24 h, after which TCR-transgenic CD8 + T cells and the respective antibody-derived constructs were added to the co-culture. 624.38 Mel cells were seeded at a concentration of 75,000 cells / well and after 24 h 75,000 CD8 + T cells / well were added together with 100 nM of CD2-sdAb (top left), CD7-sdA (top right), anti-CD2-F(ab’) 2 (bottom left) and anti-R3b23-sdAb (bottom right). The left y-axis shows cell-index values of tumor cells, indicated by grey planes, while the right y-axis shows the percentage of lysed tumor cells, indicated by colored lines. C , Depiction of dynamic target-cell lysis after addition of CD8 + T cells and antibody-derived constructs, which have been added at a concentration of 100 nM and 500 nM.

Article Snippet: The following cell lines were used in this study: human acute leukemia cell line ML2 (The CABRI consortium), B-cell lymphoma cell line U-698-M (DSMZ), human acute promyelocytic leukemia cell line NB4 (Cell Lines Service, CLS), acute myeloid leukemia cell line HL60 (CLS), melanoma cell line 624.38 Mel (kindly provided by E. Noessner, Munich, Germany), acute T cell leukemia cell line Jurkat, Clone E6-1 (kindly provided by J. Ruland, Munich, Germany) and retroviral packaging cell line 293Vec-RD114 (BioVec Pharma).

Techniques: Enzyme-linked Immunosorbent Assay, Incubation, Control, Transduction, Standard Deviation, Transgenic Assay, Derivative Assay, Construct, Co-Culture Assay, Concentration Assay, Lysis

Journal: bioRxiv

Article Title: Single-domain antibodies targeting the pan-T-cell markers CD2 and CD7 as universal immunotherapy T-cell tracers

doi: 10.64898/2025.12.23.693936

Figure Lengend Snippet: A , Experimental setup of in vivo tumor rejection model for CD8 + T cells. NSG mice were subcutaneously (s.c.) injected with ML2-B7 cells in the right flank and ML2-B15 cells in the left flank. After eight days, TCR-transgenic human CD8 + T cells were injected intravenously (i.v.) through the tail vein, followed three days later by i.v. injection of R3-b23-sdAb, OKT11, RPA, CD2-sdAb or CD7-sdAb. Tumor growth was monitored from tumor onset until the end of experiment at day twelve. B, C, Monitoring of tumor growth kinetics of ML2-B15 (B) and ML2-B7 tumors (C) in NSG mice. On day 0, eight days after subcutaneous tumor injection, mice were intravenously injected with TCR 2.5D6-transgenic CD8 + T cells and three days later with either PBS, R3b23-sdAb, CD2-F(ab’) 2 (OKT11), CD2-F(ab’) 2 (RPA-2.10), CD2-sdAb or CD7-sdAb. Kinetics of tumor growth were monitored daily for twelve days post T-cell injection. The experiment was ended at day twelve, at which point all relevant non-control tumors had been fully rejected. Tumor sizes are shown in mm 2 and mean values and SDs are depicted for each group of mice. PBS n = 4, R3b23-sdAb n = 3, CD2-F(ab’) 2 (OKT11) n = 6, CD2-F(ab’) 2 (RPA-2.10) n = 4, CD2-sdAb n = 5, CD7-sdAb n = 5. Significance was calculated using Mann-Whitney test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001)

Article Snippet: The following cell lines were used in this study: human acute leukemia cell line ML2 (The CABRI consortium), B-cell lymphoma cell line U-698-M (DSMZ), human acute promyelocytic leukemia cell line NB4 (Cell Lines Service, CLS), acute myeloid leukemia cell line HL60 (CLS), melanoma cell line 624.38 Mel (kindly provided by E. Noessner, Munich, Germany), acute T cell leukemia cell line Jurkat, Clone E6-1 (kindly provided by J. Ruland, Munich, Germany) and retroviral packaging cell line 293Vec-RD114 (BioVec Pharma).

Techniques: In Vivo, Injection, Transgenic Assay, Control, MANN-WHITNEY

Journal: bioRxiv

Article Title: Single-domain antibodies targeting the pan-T-cell markers CD2 and CD7 as universal immunotherapy T-cell tracers

doi: 10.64898/2025.12.23.693936

Figure Lengend Snippet: A , Experimental setup for in vivo imaging of ⁶⁸Ga-NOTA-labeled sdAb in NSG mice. ML2-B7 (HLA-matched) and ML2-B15 (irrelevant control) tumors were subcutaneously injected, followed by intravenous injection of TCR-transgenic CD8⁺ T cells (2 × 10⁷ per mouse). Three groups of five mice received either ⁶⁸Ga-NOTA-CD2-sdAb, ⁶⁸Ga-NOTA-CD7-sdAb, or ⁶⁸Ga-NOTA-R3b23-sdAb, and PET/MRI scans were performed one hour post-injection (p.i.). B , PET/MRI images acquired one h p.i. of mice injected i.v. with 68 Ga-NOTA-CD2-sdAb (left) or 68 Ga-NOTA-R3b23-sdAb (right). Exemplary mice are shown in coronal, sagittal and axial orientation (A) or just in coronal orientation (B). 2 x 10 7 TCR-transgenic CD8 + T cells were injected i.v. and the injected dose of applied tracer was 13 ±1MBq per mouse. Scale bar is represented as standardized uptake value (SUV), 0.4 – 1.5 SUV. B = Bladder, K = Kidney. Green arrow = ML2-B7 tumor, white arrow = ML2-B15 tumor. C , Biodistribution of 68 Ga-activity in ML2-B7 and -B15 tumors for mice receiving CD2-sdAb or R3b23-sdAb 1.5 h post injection and after previous PET/MRI image acquisition. Mean %ID/g ± SD is depicted for each group of mice. R3b23-sdAb n = 4, CD2-sdAb n = 4. Significance was calculated using Mann-Whitney test (* p ≤ 0.05).

Article Snippet: The following cell lines were used in this study: human acute leukemia cell line ML2 (The CABRI consortium), B-cell lymphoma cell line U-698-M (DSMZ), human acute promyelocytic leukemia cell line NB4 (Cell Lines Service, CLS), acute myeloid leukemia cell line HL60 (CLS), melanoma cell line 624.38 Mel (kindly provided by E. Noessner, Munich, Germany), acute T cell leukemia cell line Jurkat, Clone E6-1 (kindly provided by J. Ruland, Munich, Germany) and retroviral packaging cell line 293Vec-RD114 (BioVec Pharma).

Techniques: In Vivo Imaging, Labeling, Control, Injection, Transgenic Assay, Activity Assay, MANN-WHITNEY

Journal: bioRxiv

Article Title: Single-domain antibodies targeting the pan-T-cell markers CD2 and CD7 as universal immunotherapy T-cell tracers

doi: 10.64898/2025.12.23.693936

Figure Lengend Snippet: A , PET/MRI images acquired one h p.i. of mice injected i.v. with 68 Ga-NOTA-CD7-sdAb (left) or 68 Ga-NOTA-R3b23-sdAb (right). Exemplary mice are shown in coronal, sagittal and axial orientation (left) or just in coronal orientation (right). 2 x 10 7 TCR-transgenic CD8 + T cells were injected i.v. and the injected dose of applied tracer was 14 ±1MBq per mouse. Scale bar is represented as standardized uptake value (SUV), 0.4 – 1.5 SUV. B = Bladder, K = Kidney. Green arrow = ML2-B7 tumor, white arrow = ML2-B15 tumor. B , Biodistribution of 68 Ga-activity in ML2-B7 and -B15 tumors for mice receiving CD7-sdAb or R3b23-sdAb 1.5 h post injection and after previous PET/MRI image acquisition. Mean %ID/g ± SD is depicted for each group of mice. R3b23-sdAb n = 4, CD7-sdAb n = 5. Significance was calculated using Mann-Whitney test (* p ≤ 0.05, ** p ≤ 0.01).

Article Snippet: The following cell lines were used in this study: human acute leukemia cell line ML2 (The CABRI consortium), B-cell lymphoma cell line U-698-M (DSMZ), human acute promyelocytic leukemia cell line NB4 (Cell Lines Service, CLS), acute myeloid leukemia cell line HL60 (CLS), melanoma cell line 624.38 Mel (kindly provided by E. Noessner, Munich, Germany), acute T cell leukemia cell line Jurkat, Clone E6-1 (kindly provided by J. Ruland, Munich, Germany) and retroviral packaging cell line 293Vec-RD114 (BioVec Pharma).

Techniques: Injection, Transgenic Assay, Activity Assay, MANN-WHITNEY